600664 Stock Overview
Engages in the research, development, manufacture, and trading of pharmaceuticals in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600664 from our risk checks.
Harbin Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.69 |
| 52 Week High | CN¥3.90 |
| 52 Week Low | CN¥2.41 |
| Beta | 0.11 |
| 11 Month Change | -7.56% |
| 3 Month Change | -11.22% |
| 1 Year Change | -18.24% |
| 33 Year Change | -6.27% |
| 5 Year Change | -31.90% |
| Change since IPO | 332.17% |
Recent News & Updates
Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings
Jun 25
We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease
May 25Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
Apr 17Shareholder Returns
| 600664 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.5% | -0.1% | 0.4% |
| 1Y | -18.2% | -15.9% | -17.8% |
Return vs Industry: 600664 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 600664 matched the CN Market which returned -17.8% over the past year.
Price Volatility
| 600664 volatility | |
|---|---|
| 600664 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600664 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600664's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9,853 | n/a | www.hayao.com |
Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trading of pharmaceuticals in China and internationally. The company offers pharmaceutical products for blood and hematopoietic, antineoplastic and immunomodulatory, respiratory, anti-inflammatory and analgesic, and chronic diseases, as well as mineral supplements, Chinese medicines, and antibiotics. It offers its products under the Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, and Shiyitang brands.
Harbin Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 600664 fundamental statistics | |
|---|---|
| Market cap | CN¥6.73b |
| Earnings (TTM) | CN¥449.71m |
| Revenue (TTM) | CN¥15.67b |
15.1x
P/E Ratio0.4x
P/S RatioIs 600664 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600664 income statement (TTM) | |
|---|---|
| Revenue | CN¥15.67b |
| Cost of Revenue | CN¥11.46b |
| Gross Profit | CN¥4.20b |
| Other Expenses | CN¥3.75b |
| Earnings | CN¥449.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 26.84% |
| Net Profit Margin | 2.87% |
| Debt/Equity Ratio | 35.3% |
How did 600664 perform over the long term?
See historical performance and comparison